Many studies found that PPARγ agonists, such as ciglitazone, rosiglitazone, and pioglitazone, exert their anti-inflammatory effects primarily by inhibiting proinflammatory mediators and antagonizing the proinflammatory functions of different cell types relevant to asthma pathophysiology in both human and animals [23–25, 53]. The gene discussed is PPARG; the disease is asthma.